1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Astellas moves into vaccine technology through Japanese deal

 
• By Ian Haydock

Astellas has signed an agreement with the Japanese bioventure REGiMMUNE to develop platform technology for the development and delivery of vaccines.

Astellas has signed an agreement with the Japanese bioventure REGiMMUNE to develop platform technology for the development and delivery of vaccines.

The partners said that the collaboration would build on Astellas's expertise in screening compounds derived from natural sources and REGiMMUNE's immune liposome technology. A major objective is to investigate novel adjuvants which may be used to enhance the potency of non-viral vaccines

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapeutic Category

China Biopharma Podcast - 14 May 2025 (Chinese Language)

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.